MYADM-AS2 and Hyperglycemia: Taken together, this indicated that VEAL2 can modulate PRKCB activity and restrict translocation of PRKCB to the cell membrane in hyperglycemia, mitigating subsequent turnover of junctional complexes and maintaining endothelial cell integrity.